The Radboud University Medical Center, is the teaching hospital affiliated with the Radboud University Nijmegen, in the city of Nijmegen in the eastern-central part of the Netherlands. The Radboud University Medical Center was founded in 1956.

There are 1,065 beds in Radboudumc.

During the past decade, Radboudumc conducted 300 clinical trials. In the 10-year time frame, 300 clinical trials started and 37 clinical trials were completed, i.e. on average, 12.3% percent of trials that started reached the finish line to date. In the past 5 years, 164 clinical trials started and 29 clinical trials were completed. i.e. 17.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Radboudumc" #1 sponsor was "Radboud University Medical Center" with 203 trials, followed by "European Organisation for Research and Treatment of Cancer - EORTC" with 20 trials sponsored, "Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)" with 11 trials sponsored, "Boehringer Ingelheim" with 8 trials sponsored and "Janssen Research & Development, LLC" with 8 trials sponsored. Other sponsors include 159 different institutions and companies that sponsored additional 100 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Radboudumc" #1 collaborator was "Radboud University Medical Center" with 26 trials as a collaborator, "Dutch Cancer Society" with 17 trials as a collaborator, "ZonMw: The Netherlands Organisation for Health Research and Development" with 15 trials as a collaborator, "Erasmus Medical Center" with 14 trials as a collaborator and "UMC Utrecht" with 13 trials as a collaborator. Other collaborators include 361 different institutions and companies that were collaborators in the rest 234 trials.

According to Clinical.Site data, the most researched conditions in "Radboudumc" are "Colorectal Cancer" (10 trials), "Breast Cancer" (9 trials), "Prostate Cancer" (8 trials), "Ulcerative Colitis" (7 trials) and "Cancer" (6 trials). Many other conditions were trialed in "Radboudumc" in a lesser frequency.

Most popular intervention types in "Radboudumc" are "Drug" (203 trials), "Other" (62 trials), "Procedure" (61 trials), "Biological" (29 trials) and "Device" (28 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (44 trials), "cisplatin" (8 trials), "doxorubicin hydrochloride" (7 trials), "etoposide" (7 trials) and "Pembrolizumab" (6 trials). Other intervention names were less common.

The vast majority of trials in "Radboudumc" are 343 trials for "All" genders, 37 trials for "Female" genders and 33 trials for "Male" genders.

Currently, there are 164 active trials in "Radboudumc". 3 are not yet recruiting, 112 are recruiting, 46 are Active, not recruiting, and 3 are Enrolling by invitation. In total, there were 164 completed trials in Radboudumc, undefined suspended trials, and 26 terminated clinical trials to date.

Out of the total trials that were conducted in Radboudumc, 34 "Phase 1" clinical trials were conducted, 88 "Phase 2" clinical trials and 97 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 29 trials, and there were also 94 trials that are defined as “Not Applicable".